Analysis of 4 blood culture bottles' adsorption capacity to 4 commonly used antibiotics

doi:10.3969/j.issn.1673-8640.2024.06.011

Abstract

Abstract:

Objective To analyze the adsorption capacity of 4 kinds of blood culture bottles to imipenem，piperacillin-tazobactam，vancomycin and caspofungin，and to provide a reference for improving the determination rate of pathogens in blood culture. Methods Four antibiotics（imipenem，piperacillin-tazobactam，vancomycin and caspofungin） paired with sensitive and standard isolates were used，and blood culture was performed in 4 types of blood culture bottles（FA plus，FN plus，Aerobic and Anaerobic）. The adsorption capacity of different blood culture bottles to 4 antibiotics was evaluated according to the positive situation and positive alarm time of blood culture bottles. Results Control bottles（without antibiotic adsorption measures） showed no positivity after 5 d culture. The positive alarm rates were 75.0%（15/20） on FA plus，100.0%（10/10） on FN plus，70.0%（14/20） on Aerobic and 0.0%（0/10） on Anaerobic. Only FN plus showed positivity in imipenem/Escherichia coli group，and the positive alarm time was （12.4±0.3）h. FA plus，Aerobic and Anaerobic showed no positivity for 5 d. In piperacillin-tazobactam/Pseudomonas aeruginosa group，FA plus and Aerobic showed positivity（5/5），and the positive alarm times were 16.2±0.3 and （18.1±0.4）h，respectively（P<0.05）. FA plus，FN plus and Aerobic reported positivity in vancomycin/Staphylococcus aureus group，and the positive alarm times were 16.7±0.4，24.1±0.6 and （31.3±3.9）h，respectively（P<0.05），and Anaerobic showed no positivity for 5 d. FA plus and Aerobic reported positivity in caspofungin/Candida albicans group，and the positive alarm times were 47.1±3.3 and （42.9±2.0）h（P<0.05）. Conclusions FN plus has the capacity to adsorb imipenem and vancomycin，while FA plus and Aerobic have the capacity to adsorb vancomycin，piperacillin-tazobactam and caspofungin. For patients who have used antibiotics before blood sample collection，it is not recommended to use blood culture bottles without antibiotic adsorption measures，and appropriate blood culture bottles should be selected according to clinical antibiotic use habits.

Key words: Blood culture, Antibiotic adsorption, Pathogen, Positive alarm time

CLC Number:

R446.5

YANG Huilin, CHEN Juan, YAN Jinjin, OU Jiawen, WEN Mingming, ZHOU Lina. Analysis of 4 blood culture bottles' adsorption capacity to 4 commonly used antibiotics[J]. Laboratory Medicine, 2024, 39(6): 578-582.

Figures/Tables 3

References 11

[1]	KUMAR A, ELLIS P, ARABI Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock[J]. Chest, 2009, 136(5):1237-1248. DOI PMID
[2]	Clinical and Laboratory Standards Institute. Principles and procedures for blood cultures[S]. M47-ed2,CLSI, 2022.
[3]	DAVID N G, HENRY F C, GEORGE M E, 等. 桑福德热病抗微生物治疗指南[M]. 范洪伟, 王焕玲, 周宝桐, 等, 译. 48版. 北京: 中国协和医科大学出版社, 2019.
[4]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-ed32,CLSI, 2022.
[5]	CHUNG Y, KIM I H, HAN M, et al. A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture bottles and BD BACTEC Plus Aerobic and Anaerobic blood culture bottles for antimicrobial neutralization[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(12):2229-2233.
[6]	PIEN B C, SUNDARAM P, RAOOF N, et al. The clinical and prognostic importance of positive blood cultures in adults[J]. Am J Med, 2010, 123:819-828. DOI PMID
[7]	RANSOM E M, BURNHAM C D. Routine use of anaerobic blood culture bottles for specimens collected from adults and children enhances microorganism recovery and improves time to positivity[J]. J Clin Microbiol, 2022, 60(9):e0050022.
[8]	ADAMIK M, HUTCHINS A, MANGILIT J, et al. Effect of delayed entry on performance of the BACT/ALERT FAN PLUS bottles in the BACT/ALERT VIRTUO blood culture system[J]. Eur J Clin Microbiol Infect Dis, 2021, 40:699-705.
[9]	REIMER L G, WILSON M L, WEINSTEIN M P. Update on detection of bacteremia and fungemia[J]. Clin Microbiol Rev, 1997, 10:444-465. DOI PMID
[10]	郑炘, 黄绮, 邢珊, 等. 2种抗菌药物吸附材料血培养瓶BacT/ALERT检测平台病原体检出能力比较[J]. 检验医学, 2021, 36(12):1258-1263. DOI
[11]	LOVERN D, KATZIN B, JOHNSON K, et al. Antimicrobial binding and growth kinetics in BacT/ALERT® FA Plus and BACTEC® Aerobic/F Plus blood culture media[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(12):2033-2036.

抗菌药物	试验药物浓度（血药峰浓度）/（μg·mL^-1）	试验菌株	试验菌株MIC/（μg·mL^-1）	接种血培养瓶
抗菌药物	试验药物浓度（血药峰浓度）/（μg·mL^-1）	试验菌株	试验菌株MIC/（μg·mL^-1）	试验瓶	接种后瓶内药物浓度/（μg·mL^-1）	抗菌药物有效性对照瓶
亚胺培南	40	大肠埃希菌（ATCC 25922）	0.06~0.25	FA Plus、FN Plus Aerobic、Anaerobic	10.0（FA Plus、Aerobic） 8.0（FN Plus、Anaerobic）	SN
哌拉西林- 他唑巴坦	242/24	铜绿假单胞菌（ATCC 27853）	1/4~4/4	FA Plus、Aerobic	60.5/6.0	SA
万古霉素	50	金黄色葡萄球菌（ATCC 29213）	0.5~2.0	FA Plus、FN Plus Aerobic、Anaerobic	12.5（FA Plus、Aerobic） 10.0（FN Plus、Anaerobic）	SN
卡泊芬净	9.9	白念珠菌（ATCC 90028）	0.1	FA Plus、Aerobic	2.5	SA

抗菌药物	试验药物浓度（血药峰浓度）/（μg·mL^-1）	试验菌株	试验菌株MIC/（μg·mL^-1）	接种血培养瓶
抗菌药物	试验药物浓度（血药峰浓度）/（μg·mL^-1）	试验菌株	试验菌株MIC/（μg·mL^-1）	试验瓶	接种后瓶内药物浓度/（μg·mL^-1）	抗菌药物有效性对照瓶
亚胺培南	40	大肠埃希菌（ATCC 25922）	0.06~0.25	FA Plus、FN Plus Aerobic、Anaerobic	10.0（FA Plus、Aerobic） 8.0（FN Plus、Anaerobic）	SN
哌拉西林- 他唑巴坦	242/24	铜绿假单胞菌（ATCC 27853）	1/4~4/4	FA Plus、Aerobic	60.5/6.0	SA
万古霉素	50	金黄色葡萄球菌（ATCC 29213）	0.5~2.0	FA Plus、FN Plus Aerobic、Anaerobic	12.5（FA Plus、Aerobic） 10.0（FN Plus、Anaerobic）	SN
卡泊芬净	9.9	白念珠菌（ATCC 90028）	0.1	FA Plus、Aerobic	2.5	SA

抗菌药物/菌株组合	试验瓶			对照瓶			抗菌药有效性对照瓶/（个/个）
抗菌药物/菌株组合	报阳瓶数/个	试验瓶数/个	阳性报警时长/h	报阳瓶数/个	试验瓶数/个	阳性报警时长/h	抗菌药有效性对照瓶/（个/个）
亚胺培南/大肠埃希菌
FA plus	0	5	未报阳	2	2	12.6±0.4	0/2（SN）
FN plus	5	5	12.4±0.3	2	2	12.3±0.0
Aerobic	0	5	未报阳	2	2	11.3±0.1
Anaerobic	0	5	未报阳	2	2	11.1±0.2
哌拉西林-他唑巴坦/铜绿假单胞菌
FA plus	5	5	16.2±0.3	2	2	16.8±0.1	0/2（SA）
Aerobic	5	5	18.1±0.4	2	2	17.6±0.0
万古霉素/金黄色葡萄球菌
FA plus	5	5	16.7±0.4	2	2	14.4±0.4	0/2（SN）
FN plus	5	5	24.1±0.6	2	2	20.7±0.2
Aerobic	4	5	31.3±3.9	2	2	17.4±0.4
Anaerobic	0	5	未报阳	2	2	19.2±0.3
卡泊芬净/白念珠菌
FA plus	5	5	47.1±3.3	2	2	28.0±0.4	0/2（SA）
Aerobic	5	5	42.9±2.0	2	2	25.2±1.6

抗菌药物/菌株组合	试验瓶			对照瓶			抗菌药有效性对照瓶/（个/个）
抗菌药物/菌株组合	报阳瓶数/个	试验瓶数/个	阳性报警时长/h	报阳瓶数/个	试验瓶数/个	阳性报警时长/h	抗菌药有效性对照瓶/（个/个）
亚胺培南/大肠埃希菌
FA plus	0	5	未报阳	2	2	12.6±0.4	0/2（SN）
FN plus	5	5	12.4±0.3	2	2	12.3±0.0
Aerobic	0	5	未报阳	2	2	11.3±0.1
Anaerobic	0	5	未报阳	2	2	11.1±0.2
哌拉西林-他唑巴坦/铜绿假单胞菌
FA plus	5	5	16.2±0.3	2	2	16.8±0.1	0/2（SA）
Aerobic	5	5	18.1±0.4	2	2	17.6±0.0
万古霉素/金黄色葡萄球菌
FA plus	5	5	16.7±0.4	2	2	14.4±0.4	0/2（SN）
FN plus	5	5	24.1±0.6	2	2	20.7±0.2
Aerobic	4	5	31.3±3.9	2	2	17.4±0.4
Anaerobic	0	5	未报阳	2	2	19.2±0.3
卡泊芬净/白念珠菌
FA plus	5	5	47.1±3.3	2	2	28.0±0.4	0/2（SA）
Aerobic	5	5	42.9±2.0	2	2	25.2±1.6

[1]	LI Anqi, ZHANG Shuya, HE Shanna, CHEN Qiaoqiao, LÜ Qi, LÜ Wanfei, LI Chunxian, WANG Weihua, ZHENG Lin. Rapid bacterial identification and drug susceptibility test of blood culture-positive samples [J]. Laboratory Medicine, 2024, 39(3): 243-248.
[2]	ZHAO Yanan, CAO Qixin, YAN Yan, LI Xiaocong, ZHAO Jianping, XIAO Weili. Research progress of CRISPR/Cas13 system for pathogen detection [J]. Laboratory Medicine, 2023, 38(8): 800-804.
[3]	MA Kaihui, LÜ Zhi, ZHOU Yanyan, SU Jianrong. Characteristic analysis of Clostridium difficile colonization and infection in inpatients [J]. Laboratory Medicine, 2023, 38(2): 153-156.
[4]	REN Yanfei, ZHANG Min, YANG Tao, LI Rongkai, LIANG Xin. Analysis of pathogenic epidemiology of patients with lower respiratory tract infection in respiratory intensive care unit [J]. Laboratory Medicine, 2023, 38(2): 157-162.
[5]	TIAN Yuanyuan, JIA Xiongfei. Advantages and pathogenicity of Enterococci [J]. Laboratory Medicine, 2023, 38(11): 1101-1105.
[6]	CHEN Hanlu, WU Shenghai. Influence factors of blood culture negative results and progress of pathogen detection in bloodstream infection [J]. Laboratory Medicine, 2022, 37(7): 688-694.
[7]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[8]	CHU Minjun, LI Xiaojuan, HUANG Hailin, LI Jue, MA Mingbiao, DU Tingyi, WANG Haiping. Influence of delayed entry on fastidious bacterium culture in 2 blood culture systems [J]. Laboratory Medicine, 2022, 37(3): 209-212.
[9]	PAN Yunqi, LI Yungai, WANG Jianqiang, WU Qiong, TANG Jin. Analysis of molecular typing,virulence genes and antibiotic susceptibility of uropathogenic Escherichia coli in patients with recurrent urinary tract infection [J]. Laboratory Medicine, 2022, 37(2): 141-145.
[10]	YANG Xi, SONG Wenqi, DONG Fang, MENG Qingying, ZHEN Jinghui, ZHOU Wei. Application of Gram staining and MALDI-TOF MS in the rapid identification of pathogen kinds in children's positive blood culture [J]. Laboratory Medicine, 2022, 37(10): 969-973.
[11]	LIU Hongqian, SONG Chaohui, LIANG Qiaomi. Establishment and clinical application of multiple RT-PCR MassARRAY for the determinations of 27 respiratory pathogens [J]. Laboratory Medicine, 2021, 36(9): 939-946.
[12]	HE Ping'an, LU Yanzhou, YANG Xu, LÜ Mei, XIA Qing, LI Qingrong. Research progress in burn infection pathogens and drug resistance with the length of stay during hospitalization [J]. Laboratory Medicine, 2021, 36(9): 973-975.
[13]	LI Yanchun, TIAN Bin, YUE Na, HU Zhidong. Analysis for distribution and drug resistance of fungemia pathogen from 2014 to 2020 in a Tianjin hospital [J]. Laboratory Medicine, 2021, 36(8): 800-804.
[14]	WANG Bowen, ZENG Xiaohua, PENG Kaige, LIU Chang, WU Yingchao, HUANG Yingmei, MA Panpan, Lamuciren , LI Guokai, YANG Li. Influence of different inactivating conditions on nucleic acid determination for respiratory pathogens [J]. Laboratory Medicine, 2021, 36(8): 805-808.
[15]	YU Jiajia, LI Yuanrui, LIU Ying. MALDI-TOF MS combined with SDS and SAP pretreatment for rapid identification of positive blood culture [J]. Laboratory Medicine, 2021, 36(8): 864-868.